---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-010802"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2025-01-30T23:59:59+00:00"
generated_at: "2026-05-27T05:43:39.088216+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MindMed doses first patient in Phase 3 Panorama study of MM120 for GAD; data H2 2026

## Summary
- First patient dosed in Panorama, second Phase 3 study of MM120 ODT (LSD) for generalized anxiety disorder.
- Study will enroll ~250 participants at US/European sites; randomized 2:1:2 to 100µg, 50µg, or placebo.
- Primary endpoint: change from baseline in HAM-A at Week 12 for MM120 ODT 100µg vs placebo.
- Topline data from 12-week double-blind period anticipated in second half of 2026.
- Builds on positive Phase 2b results; first Phase 3 study Voyage also recently launched.

## SEC filing metadata
- accession: 0000950170-25-010802
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2025-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017025010802/0000950170-25-010802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017025010802/mnmd-20250130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-010802
- JSON: https://secwatch.observer/filing/0000950170-25-010802.json
- Plain text: https://secwatch.observer/filing/0000950170-25-010802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.